Skip to main content
Clinical Trials/CTRI/2018/04/013091
CTRI/2018/04/013091
Completed
Phase 3

A Comparative, Randomized, Two Arm, Double Blind, Parallel group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Ripasudil Hydrochloride Hydrate Eye Drops 0.4% w/v Vs Timolol Maleate Eye Drops 0.5% w/v in Subjects Suffering from Ocular Hypertension / Glaucoma.

Ajanta Pharma Ltd0 sites217 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: null- Ocular Hypertension/GlaucomaHealth Condition 2: H408- Other glaucoma
Sponsor
Ajanta Pharma Ltd
Enrollment
217
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 6, 2018
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects with IOP between 22mm Hg â?? 30mm Hg at the time of screening in any one eye. Incase both the eyes of a single subject are affected then the eye fulfilling the criteria will be considered for the evaluations. If both eyes are fulfilling the criteria, then the right eye will be considered for the study.
  • 2\.Voluntary willingness of patient to give written informed consent prior to participation in trial.

Exclusion Criteria

  • 1\.Women who are not using an effective means of contraception or who are pregnant or nursing.
  • 2\.Subjects with any severe or advanced cases of Glaucoma
  • 3\.Shaffer angle grade \< 2 in either eye (range, 0 \[complete or partial closure] to 3 \[wide open angle, \> 20]), as measured by Gonioscopy.
  • 4\.Subjects who are blind or subjects who have a single eye.
  • 5\.Severe central visual field loss in either eye measured by Perimetry.
  • 6\.Cup/disc ratio greater than 0\.80\.
  • 7\.Subject who are schedule to undergo surgery of the eye during the study period.
  • 8\.History of/current chronic, recurrent or severe inflammatory eye disease (eg: scleritis, uveitis, herpes keratitis) or current other severe ocular pathology (including severe dry eye) that would affect the conduct of the study.
  • 9\.History of ocular trauma or any other intraocular surgery within the past 6 months in either eye.
  • 10\.Current/history of ocular infection or inflammation within the past 3 months as determined by patient history and/or eye examination.

Outcomes

Primary Outcomes

Not specified

Similar Trials